Corporate Profile for Iomai Corporation, dated September 29, 2000.Business Editors --(BUSINESS WIRE) The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services.
Published Date: September 29, 2000
Company Name: Iomai Corporation
Address: 2421 Pennsylvania Avenue, N.W.
Washington, DC 20037
Main Telephone
Number: 202/955-7120
Internet Home
Page Address
(URL) www.iomai.com
Chief Executive
Officer: Stanley C. Erck
Chief Financial
Officer: Jeff Daniel - accountant
Investor Relations
Contact: Russell P. Wilson
Business number: 202/955-7120
E-mail address: ofcasst@iomai.com
Industry: Biotech
Company description: Iomai is a biopharmaceutical company that is developing products using its proprietary Transcutaneous transcutaneous /trans·cu·ta·ne·ous/ (-ku-ta´ne-us) transdermal. trans·cu·ta·ne·ous adj. Transdermal. Immuno Modulation (TIM TIM Timothy TIM Technical Interchange Meeting TIM Transient Intermodulation Distortion TIM Time Is Money TIM The Invisible Man (movie) TIM Telecom Italia Mobile (Italian cellular provider) ) technology to greatly enhance human immune systems immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. in the fight against disease. TIM works through the skin as a non-invasive booster Booster - A data-parallel language. "The Booster Language", E. Paalvast, TR PL 89-ITI-B-18, Inst voor Toegepaste Informatica TNO, Delft, 1989. to the body's own immune system and can be targeted against specific diseases. TIM products are administered easily and safely - stimulating the immune system to prevent or treat disease through a skin patch skin patch, transdermal patch, or transdermal delivery system, adhesive patch used to deliver a controlled dose of a drug through the skin over a period of time. , without needles or injections. Iomai is focused on rapid commercialization of the TIM technology through strategic relationships with industry partners. The TIM project pipeline includes products for three target markets: infectious diseases infectious diseases: see communicable diseases. , cancer therapies and autoimmune therapies, all delivered through the skin, without needles. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion